sargachromenol: nerve growth factor-potentiating substance from Sargassum macrocarpum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10455044 |
| CHEMBL ID | 4085945 |
| MeSH ID | M0488504 |
| Synonym |
|---|
| sargachromenol |
| CHEMBL4085945 , |
| bdbm50267968 |
| (2z,6e)-9-(6-hydroxy-2,8-dimethylchromen-2-yl)-6-methyl-2-(4-methylpent-3-enyl)nona-2,6-dienoic acid |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 (µMol) | 97.3000 | 0.0000 | 0.9453 | 9.9400 | AID1486115 |
| Beta-secretase 1 | Homo sapiens (human) | IC50 (µMol) | 7.0000 | 0.0006 | 1.6194 | 10.0000 | AID1486117 |
| Beta-secretase 1 | Homo sapiens (human) | Ki | 2.9000 | 0.0003 | 1.3524 | 8.0000 | AID1486119 |
| Cholinesterase | Equus caballus (horse) | IC50 (µMol) | 9.4000 | 0.0000 | 2.2214 | 9.4000 | AID1486116 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| amyloid-beta binding | Beta-secretase 1 | Homo sapiens (human) |
| endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| protein binding | Beta-secretase 1 | Homo sapiens (human) |
| peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| beta-aspartyl-peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| enzyme binding | Beta-secretase 1 | Homo sapiens (human) |
| protein serine/threonine kinase binding | Beta-secretase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1486117 | Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by FRET assay | 2017 | Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15 | BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. |
| AID1486116 | Inhibition of equine serum BChE using butyrylthiocholine chloride as substrate incubated for 15 mins by spectrophotometric analysis | 2017 | Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15 | BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. |
| AID1486119 | Noncompetitive inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by Dixon plot analysis | 2017 | Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15 | BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. |
| AID1486115 | Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 15 mins by spectrophotometric analysis | 2017 | Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15 | BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. |
| AID1486121 | Noncompetitive inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by Lineweaver-Burk plot analysis | 2017 | Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15 | BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||